GENFAR
Live / Registered — Registered (as of 17 Feb 2026)
What this means for you
Registered since 17 Feb 2026. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98504518
- Registration number
- 8140449
- Mark type
- Word mark
- Filed
- 17 Apr 2024
- Published for opposition
- 30 Dec 2025
- Registered
- 17 Feb 2026
- Attorney of record
- Stacy J. Grossman
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical products of chemical synthesis and biologics for human use for the prevention and treatment of acute and chronic diseases for different age groups relating to the nervous system, cardiovascular system, respiratory system, endocrine system, digestive system, genitourinary system, musculoskeletal system, sensory systems, hematopoietic system, and immune system; Pharmaceutical products in the form of prescription and non-prescription drugs, namely, pills, tablets, capsules, granulates, sachets, drops, syrups, injectables, inhalers, patches, creams, gels, suppositories, ovules, implants, and any pharmaceutical form that allows adequate administration of the drug, all for the prevention and treatment of chronic diseases for different age groups relating to the nervous system, cardiovascular system, respiratory system, endocrine system, digestive system, genitourinary system, musculoskeletal system, sensory systems, hematopoietic system, and immune system; Pharmaceutical preparations for the treatment and prevention of acute and chronic diseases of the nervous, cardiovascular, respiratory, endocrine, digestive, genitourinary, musculoskeletal, sensory, hematopoietic, and immune systems; drugs in the nature of pharmaceutical preparations for the treatment of infections caused by bacteria, viruses, fungi, parasites, and other germs; Chemical and biological preparations for medical and pharmaceutical uses for the treatment and prevention of acute and chronic diseases relating to infectious diseases, neurological diseases, psychiatric conditions, endocrinological diseases, digestive diseases, cardiovascular diseases, renal diseases, respiratory diseases, sense organ diseases, musculoskeletal diseases, and male and female reproductive organ diseases relating to contraceptives, immunological diseases, allergic conditions, inflammatory diseases, skin and adnexa dermatological diseases, oncological conditions, and hematopoietic diseases; Vaccines; Baby food; Medical plasters; Dressing materials, namely, medical dressings; Disinfectants; Vitamins; Vitamin preparations; Food supplements for medicinal purposes; Mineral food supplements for medicinal purposes; Nutritional supplements; Herbal preparations for medicinal purposes; Food supplements containing protein, carbohydrates, fat, fiber and micronutrients in the form of vitamins, mineral supplements, amino acid preparations for medicinal purposes and fatty acids for medicinal purposes
- Class 035 — Advertising and business services: Business representative services in the nature of independent sales representatives, and import-export agencies, all in the fields of pharmaceutical products, pharmaceutical preparations, medicines for human and veterinary health, antibiotics, dermatological, ophthalmological, otological and homeopathic medicines, medicines for animal health and other medicines for the defense and protection of human and veterinary health
Owner
- Genfar S.A., Bogotá D.C., CO
- Genfar S.A., Bogotá D.C., CO
- Genfar S.A., Bogotá D.C., CO
Prosecution history
- 17 Feb 2026 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 17 Feb 2026 — REGISTERED-PRINCIPAL REGISTER
- 30 Dec 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 30 Dec 2025 — PUBLISHED FOR OPPOSITION
- 24 Dec 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 03 Dec 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 03 Dec 2025 — EXAMINER'S AMENDMENT ENTERED
- 03 Dec 2025 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 03 Dec 2025 — EXAMINERS AMENDMENT E-MAILED
- 03 Dec 2025 — EXAMINERS AMENDMENT -WRITTEN
- 02 Dec 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 02 Dec 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 02 Dec 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 26 Nov 2025 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 26 Nov 2025 — NON-FINAL ACTION E-MAILED